Retraction: miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma (International Journal of Oncology (2014) 45 (1537-1546) DOI: 10.3892/ijo.2014.2577);miR-222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1537-1546

  Liu, Kai ^a   Liu, Songyang ^a   Zhang, Wei ^a   Ji, Bai ^a   Wang, Yingchao ^a   Liu, Yahui ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; miR 222; miRNA; Sorafenib

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; MICRORNA 222; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; MICRORNA; MIRN222 MICRORNA, HUMAN; NICOTINAMIDE;

ADULT; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSFECTION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84907473985     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2021.5280     Document Type: Erratum

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA and McGlynn KA: Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 54: 463-471, 2011.
3. Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346, 2002. (Pubitemid 35154440)
4. Newell P, Villanueva A and Llovet JM: Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J Hepatol 49: 1-5, 2008.
5. Ma P and Mumper RJ: Anthracycline nano-delivery systems to overcome multiple drug resistance: a comprehensive review. Nano Today 8: 313-331, 2013.
6. Vanderlaag K, Wang W, Fayadat-Dilman L, et al: Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer. Int J Cancer 130: 1251-1263, 2012.
7. Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46: 308-316, 2010.
8. Schneider E and Cowan KH: Multiple drug resistance in cancer therapy. Med J Aust 160: 371-373, 1994.
9. Pillai RS, Bhattacharyya SN, Artus CG, et al: Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 309: 1573-1576, 2005. (Pubitemid 41266485)
10. Anglicheau D, Muthukumar T and Suthanthiran M: MicroRNAs: small RNAs with big effects. Transplantation 90: 105-112, 2010
11. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002. (Pubitemid 35403967)
12. Takamizawa J, Konishi H, Yanagisawa K, et al : Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756, 2004. (Pubitemid 38697282)
13. Meng F, Henson R, Lang M, et al: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130: 2113-2129, 2006. (Pubitemid 43816961)
14. Woods K, Thomson JM and Hammond SM: Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 282: 2130-2134, 2007. (Pubitemid 47076737)
15. Wang H, Xu C, Kong X, et al : Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. PLoS One 9: e99067, 2014.
16. Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF and Pogribny IP: MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics 2: 171-185, 2011.
17. Stinson S, Lackner MR, Adai AT, et al: miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal 4: pt5, 2011.
18. Yang CJ, Shen WG, Liu CJ, et al: miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. J Oral Pathol Med 40: 560-566, 2011.
19. Lu Y, Roy S, Nuovo G, et al: Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 286: 42292-42302, 2011.
20. Miller TE, Ghoshal K, Ramaswamy B, et al: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27 Kip1. J Biol Chem 283: 29897-29903, 2008.
21. Zhang CZ, Zhang JX, Zhang AL, et al: MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9: 229, 2010.
22. Xu K, Liang X, Shen K, et al: MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res 318: 2168-2177, 2012.
23. Wong QW, Ching AK, Chan AW, et al: MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 16: 867-875, 2010.
24. Zhong S, Li W, Chen Z, Xu J and Zhao J: MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene 531: 8-14, 2013.
25. Garofalo M, Di Leva G, Romano G, et al: miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16: 498-509, 2009.
26. Wittekind C: Pitfalls in the classification of liver tumors. Pathologe 27: 289-293, 2006 (In German).
27. Tio TL: The TNM staging system. Gastrointest Endosc 43: S19-S24, 1996.
28. Gao Q, Qiu SJ, Fan J, et al: Intratumor balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593, 2007. (Pubitemid 47041232)
29. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 365: 1118-1127, 2011.
30. Bruix J, Sherman M and American Association for the Study of Liver D: Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.
31. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
32. Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858, 2006. (Pubitemid 46094197)
33. Roy M, Luo YH, Ye M and Liu J: Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. Biomed Res Int 2013: 964743, 2013.
34. Bai S, Nasser MW, Wang B, et al: MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284: 32015-32027, 2009.
35. Yang F, Li QJ, Gong ZB, et al: MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat 13: 77-86, 2014.
36. Galardi S, Mercatelli N, Giorda E, et al: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27 Kip1. J Biol Chem 282: 23716-23724, 2007. (Pubitemid 47311902)
37. Yang X, Yang Y, Gan R, et al: Down-regulation of miR-221 and miR-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. PLoS One 9: e98833, 2014.
38. Chen Y, Zaman MS, Deng G, et al: MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res 4: 76-86, 2011.
39. Sun T, Wang X, He HH, et al: MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene 33: 2790-2800, 2014.
40. Li W, Tan D, Zhang Z, Liang JJ and Brown RE: Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep 20: 713-719, 2008.
41. Chen JS, Wang Q, Fu XH, et al: Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 39: 177-186, 2009.
42. Krasilnikov M, Ivanov VN, Dong J and Ronai Z: ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22: 4092-4101, 2003. (Pubitemid 36819649)
43. Saxena NK, Sharma D, Ding X, et al: Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67: 2497-2507, 2007. (Pubitemid 46548934)
44. Chen KF, Chen HL, Tai WT, et al: Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 337: 155-161, 2011.